XML 1020 R46.htm IDEA: XBRL DOCUMENT v2.4.0.6
Significant Contracts (Details) (USD $)
In Millions, unless otherwise specified
 1 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended
Apr. 30, 2011
Daiichi Sankyo
Sep. 30, 2012
Daiichi Sankyo
Dec. 31, 2011
Daiichi Sankyo
Jul. 31, 2011
Daiichi Sankyo
Minimum
country
Sep. 30, 2012
Daiichi Sankyo
Minimum
Dec. 31, 2011
Daiichi Sankyo
Minimum
Sep. 30, 2012
Daiichi Sankyo
Maximum
Dec. 31, 2011
Daiichi Sankyo
Maximum
Oct. 31, 2007
ALIGN
item
Dec. 31, 2010
ALIGN
Dec. 31, 2009
ALIGN
Dec. 31, 2011
ALIGN
Licensing Agreements                        
Up-front fee and certain past reimbursements $ 1.6                      
Future milestone payments payable   10.0 10.0                  
Period for which royalties will be paid following the first commercial sale of licensed products in the country   10 years 10 years                  
Notice period for termination of license by the entity for technical, scientific, efficacy, safety, or commercial reasons   6 months 6 months                  
Notice period for termination of license after launch of a sapacitabine-based product by the entity, or by either party for material default   12 months 12 months                  
Number of countries for which regulatory approval is required by September 2011 to sell sapacitabine as per termination right waived after amendment to the agreement       1                
Percentage of increase in royalty due on future net sales of sapacitabine after amendment         1.25% 1.25% 1.50% 1.50%        
Number of products for which exclusive rights acquired to sell and distribute products                 3      
Commitment payments                     1.3  
Commitment paid                   0.7 0.6  
Minimum purchase obligation                       $ 0.2